Trade Names:Thioridazine Hydrochloride- Tablets 10 mg- Tablets 15 mg- Tablets 25 mg- Tablets 50 mg- Tablets 100 mg- Tablets 150 mg- Tablets 200 mg- Oral Concentrate 30 mg/mL- Oral Concentrate 100 mg/mLApo-Thioridazine (Canada)
Effects apparently caused by dopamine receptor blocking in CNS.
Management of schizophrenia.
Congenital QT interval prolongation; concurrent drugs that prolong the QT interval; history of cardiac arrhythmias; comatose or severely depressed states; allergy to this or any phenothiazine; presence of large amounts of other CNS depressants; severe hypotension or hypertension.
PO Start with 50 to 100 mg 3 times daily, increasing the dose gradually in increments (max, 800 mg/day). Total daily dose ranges from 200 to 800 mg divided into 2 to 4 doses.Children
PO Start with 0.5 mg/kg/day in divided doses, increasing the dose gradually until optimal therapeutic effect is obtained (max, 3 mg/kg/day).
Store tablets and oral concentrate at controlled room temperature (59° to 86°F).
May result in increased CNS depression and may precipitate extrapyramidal reaction.Anticholinergics
May reduce therapeutic effects of thioridazine and worsen anticholinergic effects of thioridazine. May lead to tardive dyskinesia.Barbiturate anesthetics
Frequency and severity of neuromuscular excitation and hypotension may increase.Beta-blockers
May result in increased plasma levels of beta-blocker and thioridazine.Drugs that prolong the QT interval (eg, cisapride), drugs that inhibit CYP2D6 (eg, fluoxetine, paroxetine)
May increase the risk of life-threatening cardiac arrhythmias, including torsades de pointes. Coadministration of these agents is contraindicated.Drugs that reduce the Cl of thioridazine by other mechanisms (eg, fluvoxamine, propranolol, pindolol)
May elevate plasma levels of thioridazine, increasing the risk of side effects including life-threatening cardiac arrhythmias. Avoid coadministration of these agents.Epinephrine
May antagonize effects of epinephrine.Lithium
May cause disorientation, unconsciousness, and extrapyramidal effects.
May discolor urine pink to red-brown. False-positive pregnancy test results may occur, but are less likely to occur with serum test. Increases in protein bound iodine have been reported.
Orthostatic hypotension; hypertension; tachycardia; bradycardia; syncope; cardiac arrest; circulatory collapse; lightheadedness; faintness; dizziness; EKG changes, including dose-related prolongation of the QTc interval.
Pseudoparkinsonism; dystonias; motor restlessness; headache; weakness; tremor; fatigue; slurring; insomnia; vertigo; seizures; tardive dyskinesia; drowsiness; paradoxical excitement; headache; confusion.
Photosensitivity; skin pigmentation; dry skin; exfoliative dermatitis; urticarial rash; maculopapular hypersensitivity reaction; seborrhea; eczema.
Pigmentary retinopathy; glaucoma; photophobia; blurred vision; mydriasis; increased IOP; dry throat; nasal congestion.
Dyspepsia; constipation; dry mouth; adynamic ileus; nausea; vomiting; diarrhea.
Urinary hesitancy or retention; impotence; sexual dysfunction; dysmenorrhea; menstrual irregularities; uremia; breast enlargement; galactorrhea.
Agranulocytosis; eosinophilia; leukopenia; hemolytic anemia; thrombocytopenic purpura.
Jaundice; biliary stasis.
Laryngospasm; respiratory depression; bronchospasm; dyspnea.
Increase in appetite and weight; polydipsia; neuroleptic malignant syndrome (NMS); allergy (including fever, laryngeal edema, angioneurotic edema, asthma); elevated prolactin levels.
QTc prolongation is dose related. Torsades de pointes-type arrhythmias and sudden death.
Reserved for use only in refractory schizophrenia that failed to show an acceptable response to adequate course of other antipsychotics.
Safety not established.
Safety not established.
More susceptible to effects; consider lower dose.
Use caution in patients with CV disease or mitral insufficiency, history of glaucoma, EEG abnormalities, or seizure disorders, prior brain damage, hepatic or renal impairment, or in those exposed to extreme heat.
May impair mental or physical abilities, especially during first few days of therapy.
Jaundice usually occurs between second and fourth wk of treatment; considered hypersensitivity reaction. Usually reversible.
Has occurred with agents of this class; is potentially fatal. Signs and symptoms are hyperpyrexia, muscle rigidity, altered mental status, irregular pulse, irregular BP, tachycardia, and diaphoresis.
Cases of bronchopneumonia (some fatal) occurred.
Sudden death reported; predisposing factors may be seizures or previous brain damage. Flare-ups of psychotic behavior may precede death.
Syndrome of potentially irreversible involuntary body and facial movements may develop. Prevalence highest in the elderly, especially women. Use smallest effective doses for shortest possible time.
Decreased consciousness, arrhythmias, extrapyramidal effects, confusion, agitation, respiratory depression, anticholinergic effects.
Copyright © 2009 Wolters Kluwer Health.